IP Library Granted Patent US 9,738,672
Granted Patent B2
US 9,738,672 · App. 15/108,547 · Granted Aug 22, 2017

Compounds, compositions, and methods for the treatment of cancers

Inventors: Mark T. Bilodeau (Concord, MA); Benoît Moreau (Newton, MA)
Assignee: PLACON THERAPEUTICS, INC.
C07F15/0093
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,738,672
App. No.
15/108,547
Granted
Aug 22, 2017
Kind
B2
Abstract

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand.

Claims (25)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 and R 2 are joined together to form cyclohexane-1,2-diamine;

R 3 and R 4 each independently is a halide or a carboxylate; and

X is absent, C(R 5 ) 2 , or NR 5 ,

Y is absent, C(R 6 ) 2 , or NR 6 ,

R 5 and R 6 independently at each occurrence is selected from hydrogen, alkyl, alkenyl, alkynyl, ether, amine, and carboxylate, wherein each of the alkyl, the alkenyl, the alkynyl, the ether, and the amine groups optionally is substituted with one or more groups, each independently selected from halogen, hydroxyl, ether, alkoxy, and amine, wherein each of the ether, the alkoxy, or the amine is optionally substituted with one or more suitable substituents;

provided that at least one of X or Y is NH; and

at least one of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 comprises a polar moiety.

2. The compound of claim 1 , wherein the compound has Formula Ia:

3. The compound of claim 1 , wherein R 3 and R 4 each is Cl.

4. The compound of claim 3 , wherein the compound has Formula IIIa:

wherein at least one of R 5 and R 6 comprises a polar moiety.

5. The compound of claim 1 , wherein R 3 and R 4 are joined together to form oxalic acid.

6. The compound of claim 5 , wherein the compound has Formula IIIb:

wherein at least one of R 5 and R 6 comprises a polar moiety.

7. The compound of claim 1 , wherein one of R 5 and R 6 is methyl.

8. The compound of claim 1 , wherein the compound is polar.

9. The compound of claim 1 , wherein the compound has a log P of less than about 2.0.

10. The compound of claim 1 , wherein the compound has a log P of less than about 1.7.

11. The compound of claim 1 , wherein the compound has a log P of less than about 1.3.

12. The compound of claim 1 , wherein the compound has a log P of less than about 1.1.

13. The compound of claim 1 , wherein the compound is selected from:

14. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2020
From: PLACON THERAPEUTICS, INC.
To: XLINK THERAPEUTICS, INC.
Reel/Frame 054215/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2016
From: BILODEAU, MARK T.; MOREAU, BENOÎT
To: PLACON THERAPEUTICS, INC.
Reel/Frame 039060/0455 →
Continuity (2)
Provisional Application 61922272 · Dec 31, 2013
Related Publication 20160318962A1 · Nov 3, 2016